Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024 Nanotech Investing
Group Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, Euro 500 Million Share Buy-Back Program Launched Nanotech Investing
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer Nanotech Investing
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update Nanotech Investing
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update Nanotech Investing
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 Nanotech Investing
Sona's Cancer Therapy Creates a Systemic Immune Response in Murine Breast Cancer Model Technology Investing
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer Nanotech Investing
